Gentium S.p.A. Provides an Update on Defibrotide MAA to European Medicines Agency

Published: Jan 17, 2013

VILLA GUARDIA, Italy, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed that the Company's Marketing Authorization Application ("MAA") for Defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation therapy will be on the agenda for discussion at the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") meetings scheduled to be held on February 18-21, 2013.

Back to news